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Purpose: To investigate interobserver variation in target volume delineations for prostate cancer salvage radiotherapy using 
planning computed tomography (CT) versus combined planning CT and magnetic resonance imaging (MRI).
Materials and Methods: Ten radiation oncologists independently delineated a target volume on the planning CT scans of 
five cases with different pathological status after radical prostatectomy. Two weeks later, this was repeated with the addition of 
planning MRI. The volumes obtained with CT only and combined CT and MRI were compared, and the effect of the addition of 
planning MRI on interobserver variability was assessed. 
Results: There were large differences in clinical target volume (CTV) delineated by each observer, regardless of the addition of 
planning MRI (9.44–139.27 cm3 in CT only and 7.77–122.83 cm3 in CT plus MRI) and no significant differences in the mean and 
standard deviation of CTV. However, there were decreases in mean volume and standard deviation as a result of using the planning 
MRI. 
Conclusion: This study showed substantial interobserver variation in target volume delineation for salvage radiotherapy. The 
combination of planning MRI with CT tended to decrease the target volume and the variation. 
Keywords: Prostate cancer, Salvage radiotherapy, Target volume, Interobserver variation, Magnetic resonance image 
Interobserver variation in target volume for salvage 
radiotherapy in recurrent prostate cancer patients after 
radical prostatectomy using CT versus combined CT and 
MRI: a multicenter study (KROG 13-11) 
Eonju Lee, MD1, Won Park, MD, PhD1, Sung Hwan Ahn, PhD1, Jae Ho Cho, MD, PhD2, Jin Hee Kim, MD, PhD3, 
Kwan Ho Cho, MD, PhD4, Young Min Choi, MD, PhD5, Jae-Sung Kim, MD, PhD6, Jin Ho Kim, MD, PhD7,  
Hong-Seok Jang, MD, PhD8, Young-Seok Kim, MD, PhD9, Taek-Keun Nam, MD, PhD10 
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul;
2Department of Radiation Oncology, Yonsei University College of Medicine, Severance Hospital, Seoul;
3Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu;
4Proton Therapy Center, National Cancer Center, Goyang;
5Department of Radiation Oncology, Dong-A University College of Medicine, Busan;
6Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam;
7Department of Radiation Oncology, Seoul National University College of Medicine, Seoul;
8Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul;
9Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul;
10Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea
Received 13 February 2017, Revised 12 June 2017, Accepted 26 June 2017.
Correspondence: Won Park, MD, PhD, Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan 
University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Tel: +82-2-3410-2616, Fax: +82-2-3410-2619, 
E-mail: wonro.park@samsung.com
Eonju Lee, et al
12 www.e-roj.org https://doi.org/10.3857/roj.2017.00080
Introduction
Salvage radiotherapy (RT) to the prostatic fossa is an effective 
therapy in patients with biochemical or local recurrence 
after radical prostatectomy (RP). The American Society for 
Radiation Oncology (ASTRO) and the American Urological 
Association (AUA) guidelines recommended salvage RT for 
treatment of biochemical or local recurrence without evidence 
of distant metastasis [1]. Several randomized trials have 
included a subgroup with detectable prostate-specific antigen 
(PSA) levels after RP. RT after RP significantly reduced local 
failure and distant metastasis and improved overall survival 
in the Southwest Oncology Group (SWOG) 8794 [2,3] and 
biochemical failure in the European Organisation for Research 
and Treatment of Cancer (EORTC) 22911 [4] among patients 
with postoperative high-risk factors or a detectable PSA 
level. Two observational studies have reported the outcomes 
of salvage RT. At a median of 11.5 years, salvage RT after RP 
significantly reduced the local recurrence risk by almost 90% 
and systemic progression by 75% [5] and was associated 
with a three-fold increase in prostate cancer-specific survival 
relative to those who received no salvage treatment [6]. 
Although salvage RT is the only potentially curative 
treatment option for recurrent prostate cancer patients 
after RP, the optimal target volume of salvage RT remains 
controversial. Several guidelines have been published for 
clinical target volume (CTV) delineation in postoperative RT 
[7-10]; however, there is no universally accepted method, and 
substantial variation exists.   
In the postoperative setting, anatomic changes that occur 
following RP may significantly alter the target definition 
compared with definitive RT for localized prostate cancer 
patients. The absence of a visible target introduces a potentially 
significant interobserver bias in defining the prostatic fossa 
CTV. 
Magnetic resonance imaging (MRI) provides greater 
resolution of soft tissues compared with computed tomography 
(CT), and it allows more precise delineation of target volume 
and normal tissues [11,12]. Therefore, MRI is commonly used 
in the planning of definitive RT for prostate cancer. Several 
studies have reported that addition of MRI to planning CT 
decreases target volume and reduces variation in prostate 
delineation [13,14]. Also, MRI has the potential to demonstrate 
the site of local recurrence after RP [7-9] and can be used for 
CTV delineation in salvage RT.  
In this study, we investigated interobserver variation in 
target volume delineation for salvage RT in recurrent prostate 
cancer patients treated with radical prostatectomy, and we 
compared the effect of addition of MRI in determination of 
CTV.  
Materials and Methods
1. Case and observer characteristics  
Planning CT scans of five sampled cases referred for salvage 
RT to the prostatic fossa because of continuous PSA elevation 
after RP were used for this target delineation study. Each case 
involved diagnostic prostate MRI before RP and planning MRI 
before salvage RT. The clinical and surgical information of the 
cases is shown in Table 1. 
Ten radiation oncologists from 10 different institutions 
participated in the study and were asked to contour the target 
volume on each of the five CT scans. Their institutions’ practice 
patterns for salvage RT are described in Table 2. 
2. Planning CT and MRI acquisition 
The planning CT and MRI scans were performed in a 
reproducible supine position with endorectal ballooning at 
same day. All patients voided their bladders immediately 
before scanning. Treatment planning CT scans of the pelvis 
were obtained in 2.5-mm slice thicknesses at 2.5-mm intervals 
using a LightSpeed RT16 scanner (GE Healthcare, St. Giles, UK). 
The MRI scans were performed with 3.0T systems (Achieva 3T, 
Philips Medical System, Best, Netherlands) using a 6-channel 
phased-array coil. Both T2-weighted images (T2WIs) and 
diffusion-weighted images (DWIs) were included in all of the 
MRI scans. The T2WIs were acquired in the three orthogonal 
planes (axial, sagittal, and coronal). The following T2WI scan 
parameters were used for this study: repetition time (TR)/
echo time (TE), 2,600-4,200 ms/80–100 ms; slice thickness, 
3 mm; interslice gap, 0.3–0.1 mm; matrix, 512×304; field-
of-view (FOV), 15–20 cm; number of signals acquired, 3; and 
sensitivity encoding (SENSE) factor, 2. The DWIs were acquired 
in the axial plane using the single-shot echo-planar imaging 
technique. The scanning parameters were as follows: TR/TE, 
2,740–2,750 ms/83–85 ms; slice thickness, 3 mm; interslice 
gap, 1 mm; matrix, 112 × 110; FOV, 20 cm; SENSE factor, 2; and 
the number of signals averaged (NSA), 3. 
3. Target volume delineation
Ten observers received the cl inical  information and 
pathological status of five cases in order to define CTV (Table 
1). The planning CT and diagnostic MRI (T2WI and DWI) scans 
were offered to each observer using an online storage system 
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and were transferred to each individual planning system. On 
every CT slice, the first contouring of CTV was performed under 
institutional practice guideline whether or not diagnostic MRI 
was performed. After an interval of 2 weeks, the planning MRI 
scans (T2WI with endorectal ballooning and DWI) of each case 
were offered and superimposed on the CT image. The second 
contouring of CTV was drawn on superimposed CT and axial 
MRI slices of each scan. All CTVs included only the prostate 
fossa (pelvic lymph node area was excluded). 
4. Analysis of interobserver variation 
After completion of contouring, planning CT images with two 
different CTVs were analyzed using the Pinnacle3 planning 
system 9.2 (Philips Medical Systems, Fitchburg, WI, USA). Data 
on each delineated target volume both on planning CT only 
(CTV1) and on CT with planning MRI (CTV2) were imported 
from the RT planning system. For each case, the average 
volume and standard deviation (SD) of the ten observer 
measurements were calculated. Subsequently, the mean of 
these averages and their SDs were calculated for both CTV1 
and CTV2. Comparisons between CTV1 and CTV2 derived values 
(mean or SD) were represented in percentage decrease, defined 
as (xCTV2–xCTV1)/xCTV1; positive values indicated that the 
CTV2 value was larger than the corresponding CTV1 value. 
Statistical analysis was executed using SAS ver. 9.3 (SAS 
Institute, Cary, NC, USA). The Wilcoxon signed-rank test was 
used to compare measurements of target volume. A linear 
mixed model was used to identify the factors that influenced 
target volume delineation. All p-values were two-sided, and 
those less than 0.05 were regarded as statistically significant.
Results
1. Interobserver variations in CTV1 and CTV2
There were large differences in CTV delineated by each 
observer, regardless of the addition of planning MRI. Table 3 
shows the CTVs determined by CTV1 and CTV2 for each case. 
Between the observers, 7- to 15-fold differences existed. 
2. Target volume change using planning MRI
There were no significant differences in mean and SD between 
CTV1 and CTV2 (50.6 ± 31.6 cm3 in CTV1 and 49.7 ± 30.6 cm3 in 
CTV2; p = 0.1875). The mean CTV2 of the observers decreased 
compared with CTV1 for all except case #1. The SD of CTV2 
Table 1. Case characteristics 
Case Initial PSA (ng/mL) Gleason score Pathologic stagea) Positive margins bDFS (mo) preRT PSA (ng/mL)
1
2
3
4
5
3.47
3.36
3.12
5.71
10.24
7
6
7
7
8
pT2cN0
pT2cN0
pT3aN0
pT3aN0
pT3bN0
No
No
No
No
Right base
23
28
77
6
40
0.33
0.22
0.50
0.24
0.31
PSA, prostate-specific antigen; bDFS, biochemical disease-free survival; RT, radiotherapy.
a) AJCC Cancer Staging Manual, 7th edition.
Table 2. Institutions’ radiotherapy practice 
Institution
No. of salvage treatment 
cases at 2012
MRI fusion for planning Endorectal ballooning Bladder filling
1
2
3
4
5
6
7
8
9
10
73
58
57
49
44
23
21
20
6
5
Yes
No
No
No
Yes
No
Yes
No
No
No
Yes
No
Yes
Yes
Yes
No
Yes
No
Yes
No
No
No
No
Yes
Yes
Yes
Yes
No
Yes
No
MRI, magnetic resonance image. 
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was also decreased compared with CTV1 for all except case #4 
(Fig. 1A). The percentage decrease in the CTVs is demonstrated 
in Fig. 1B. The observers tended to report a decreased mean 
volume and SD as a result of using the planning MRI.
3. CTV1 and CTV2 difference according to observers
The target volumes were also analyzed by each observer. Fig. 
2 shows mean CTVs and standard errors of each observer. 
Observer 10 reported the largest volume (94.7 ± 27.2 cm3 in 
CTV1 and 95.1 ± 24.6 cm3 in CTV2), and observer 1 reported 
the smallest volume (11.3 ± 1.5 cm3 in CTV1 and 10.6 ± 2.4 
cm3 in CTV2). Six observers delineated the decreased CTV (CTV2) 
using planning MRI. 
Discussion and Conclusion
In adjuvant or salvage RT after RP, there is no optimal 
consensus for CTV delineation. Several guidelines have been 
published based on the pattern of local failure. Malone et 
al. [15] compared four of the guidelines [7-10] and reported 
that the recommended CTV was significantly different among 
the guidelines. The CTVs proposed by the EORTC, the Faculty 
of Radiation Oncology Genito-Urinary Group (FROGG), the 
Radiation Therapy Oncology Group (RTOG), and the Princess 
Margaret Hospital (PMH) differ based on the recommended 
target border, especially in the cranial direction. The superior 
boundary of the CTV was defined as follows: by the bladder neck 
in the EORTC guideline; as encompassing the entire seminal 
vesicle bed and distal portion of the vas deferens in the FROGG 
guideline; as the level of the cut end of the vas deferens or 3–4 
cm above the top of the symphysis in the RTOG guideline; and 
as the superior surgical clips or 5 mm above the vas deferens 
in the PMH guideline. The volumes of the four guidelines were 
Table 3. Interobserver variations of CTV according to acquired 
planning images 
CTV1 (cm3) CTV2 (cm3)
Case 1
Case 2
Case 3
Case 4
Case 5
44.54 (9.44–92.10)
42.91 (12.87–83.92)
60.68 (12.39–139.27)
54.98 (9.97–106.16)
49.73 (11.89–94.35)
45.34 (10.6–83.4)
41.56 (8.75–81.54)
58.74 (13.96–122.83)
54.61 (7.77–119.69)
48.04 (11.71–84.66)
Values are presented as mean (range).
CTV, clinical target volume; CTV1, delineated by planning com-
puted tomography only; CTV2, delineated by planning computed 
tomography fusion with magnetic resonance image.
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Fig. 1. (A) Mean volume with standard error and (B) percentage 
decrease of clinical target volume (CTV) in each case. CTV1, 
delineated by planning computed tomography only; CTV2, 
delineated by planning computed tomography fusion with 
magnetic resonance image.
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Fig. 2. Mean volume with standard error of all 5 cases in each 
observer. CTV, clinical target volume; CTV1, delineated by planning 
computed tomography only; CTV2, delineated by planning 
computed tomography fusion with magnetic resonance image.
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60 ± 17 cm3, 88 ± 16 cm3, 102 ± 24 cm3, and 104 ± 25 cm3, 
respectively. 
Recently, we analyzed the recurrent tumor location in 113 
prostate cancer patients using MRI and suggested an optimal 
CTV, which included 97% of suspected tumor recurrences. 
Using the inferior border of the pubic symphysis as a point 
of reference, the inferior border of the CTV was 8 mm below 
and the superior border extended 30 mm above. We suggested 
that it might be unnecessary to routinely include the seminal 
vesicle bed or the surgical clips within the CTV for all patients. 
With this guideline, the mean CTV in our practice was 15 ± 5 
cm3, remarkably smaller than those of the other guidelines [16]. 
In this study, there were large differences in CTV, regardless 
of planning MRI fusion between observers. These differences 
were due to the differing CTV delineation guidelines among 
the different institutions. Our results indicate that CTV 
delineation by fusion of planning CT and planning MRI might 
reduce clinical target volume.
The organ-discriminating power on CT images is much 
lower than that on MR images. CT can be used to discriminate 
various tissues based solely on differences in attenuation 
coefficients [10]. Since the prostate, rectal and bladder wall, 
pelvic floor muscles, and penile bulb have similar attenuation 
coefficients, they cannot readily be discriminated on CT images, 
resulting in potentially significant inaccuracies. Conversely, 
MRI can be used to demonstrate and characterize soft tissues 
by providing superb soft-tissue contrast on T2WIs. MRI 
therefore shows much more detail on the prostatic margins 
in any direction, leading to more accurate delineations. 
Compared with MRI, CT images overestimate prostate volume 
by 35% [14]. Villeirs et al. [13] reported that using CT plus 
MRI compared to CT alone resulted in significant decreases 
of 6.54%, 5.21%, and 10.47% in mean CTV of prostate and 
seminal vesicle volumes, and the SDs were significantly 
decreased by 63.06%, 62.65%, and 44.83%, respectively. These 
results indicate that the addition of MRI to CT decreases the 
interobserver target volume delineation variation in definitive 
RT for prostate cancer. Therefore, this greater resolution of soft 
tissues through the use of MRI could help the delineation of 
CTV for salvage RT through the anatomic precision of prostatic 
fossa. 
Despite a substantial difference between CTVs delineated 
by each observer, a trend of volume reduction was observed in 
the mean CTV and SD when planning MRI was added. When 
we considered salvage RT procedures of 10 institutions, the 
observers using endorectal ballooning and bladder filling 
in clinical practice affected the CTV and had a tendency of 
decreasing target volume with MRI. Anatomic accuracy of 
prostatic fossa using planning MRI might be one explanation 
for the results. 
In conclusion, we show that interobserver variation in 
target volume delineation for salvage RT is substantial. The 
combination of planning MRI with CT tends to decrease the 
target volume and its variation. However, the role of MRI in 
salvage RT target delineation was insufficient, and additional 
studies are needed. Furthermore, to reduce interobserver 
variation, a consensus meeting for optimal target volume after 
RP is needed among physicians.
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